ME02206B - Receptor insulinu-sličnog faktora rasta 1 vezujući peptidi - Google Patents
Receptor insulinu-sličnog faktora rasta 1 vezujući peptidiInfo
- Publication number
- ME02206B ME02206B MEP-2015-146A MEP14615A ME02206B ME 02206 B ME02206 B ME 02206B ME P14615 A MEP14615 A ME P14615A ME 02206 B ME02206 B ME 02206B
- Authority
- ME
- Montenegro
- Prior art keywords
- polypeptide
- endothelial cells
- seq
- conjugate
- sequence shown
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (12)
1. Izolovani polipeptid koji sadrži polipeptid koji ima sekvencu prikazanu u SEK ID NO: 1 -13, pri čemu navedeni polipeptid može da:(a) se vezuje za IGF1R; i(b) bude transportovan transcitozom preko endotelijalnih ćelija.
2. Izolovani polinukleotid koji sadrži polinukleotid koji kodira polipeptid prema zahtevu 1.
3. Izolovani polinukleotid prema zahtevu 2, koji sadrži polinukleotid koji ima sekvencu prikazanu u SEQ ID NO: 14-26, ili njegova komplementarna sekvenca.
4. Izolovani vektor koji sadrži polinukleotid koji ima sekvencu prikazanu u SEK ID NO: 14-26, pri čemu navedeni polinukleotid kodira polipeptid prema zahtevu 1.
5. Vektor prema patentnom zahtevu 4, pri čemu je vektor ekspresioni vektor.
6. Izolovana ćelija domaćina koja sadrži vektor prema zahtevu 4.
7. Izolovani fuzioni protein koji sadrži polipeptid iz zahteva 1 spojen sa drugim polipeptidom.
8. Fuzioni protein prema zahtevu 7, pri čemu drugi polipeptid kodira njegov imunoglobulin ili fragment.
9. Postupak za eksprimiranje polipeptida koji sadrži sledeće korake: a. obezbeđivanje ćelije domaćina prema patentnom zahtevu 6; i b. kultivisanje ćelije-domaćina u uslovima dovoljnim za ekspresiju polipeptida prema zahtevu 1.
10. ln vitro metod za isporuku terapeutskog agensa preko endotelijalnih ćelija, koji sadrži: a. konjugovanje terapeutskog agensa sa polipeptidom koji sadrži polipeptid koji ima sekvencu prikazanu u SEK ID NO: 1, 2, 4, 8, ili 12 da se formira konjugat; b. kontaktiranje konjugata sa endotelijalnim ćelijama; i e. merenje količine konjugata isporučene preko endotelijalnih ćelija.
11. Polipeptid koji ima sekvencu prikazanu u SEK ID NO: 1, 2, 4, 8 ili 12 za upotrebu u postupku za isporuku terapeutskog agensa preko endotelijalnih ćelija, pri čemu pomenuta upotreba uključuje: a. konjugovanje terapeutskog agensa sa polipeptidom koji sadrži polipeptid koji ima sekvencu prikazanu u SEK ID NO: 1, 2, 4, 8, ili 12 da se formira konjugat; b. kontaktiranje konjugata sa endotelijalnim ćelijama; i e. merenje količine konjugata isporučenog preko endotelijalnih ćelija.
12. Postupak prema zahtevu 11, u kojem endotelijalne ćelije formiraju krvno-moždanu barijeru.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34893710P | 2010-05-27 | 2010-05-27 | |
| EP11787324.0A EP2575846B1 (en) | 2010-05-27 | 2011-05-25 | Insulin-like growth factor 1 receptor binding peptides |
| PCT/US2011/037904 WO2011150061A1 (en) | 2010-05-27 | 2011-05-25 | Insulin-like growth factor 1 receptor binding peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02206B true ME02206B (me) | 2016-02-20 |
Family
ID=45004356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-146A ME02206B (me) | 2010-05-27 | 2011-05-25 | Receptor insulinu-sličnog faktora rasta 1 vezujući peptidi |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8415306B2 (me) |
| EP (1) | EP2575846B1 (me) |
| JP (1) | JP5864556B2 (me) |
| KR (1) | KR101898502B1 (me) |
| CN (1) | CN103025341B (me) |
| AU (1) | AU2011258301B2 (me) |
| BR (1) | BR112012030084B1 (me) |
| CA (1) | CA2800744C (me) |
| CY (1) | CY1116757T1 (me) |
| DK (1) | DK2575846T3 (me) |
| EA (1) | EA023541B1 (me) |
| ES (1) | ES2550040T3 (me) |
| HR (1) | HRP20151084T1 (me) |
| HU (1) | HUE026269T2 (me) |
| IL (1) | IL223030A (me) |
| ME (1) | ME02206B (me) |
| MX (1) | MX337134B (me) |
| NZ (1) | NZ603611A (me) |
| PL (1) | PL2575846T3 (me) |
| PT (1) | PT2575846E (me) |
| RS (1) | RS54278B1 (me) |
| SG (1) | SG186068A1 (me) |
| SI (1) | SI2575846T1 (me) |
| SM (1) | SMT201500222B (me) |
| UA (1) | UA107596C2 (me) |
| WO (1) | WO2011150061A1 (me) |
| ZA (1) | ZA201209689B (me) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106459194B (zh) * | 2014-03-06 | 2019-10-18 | 加拿大国家研究委员会 | 胰岛素样生长因子1受体特异性抗体及其用途 |
| AU2014385800B2 (en) * | 2014-03-06 | 2020-10-22 | National Research Council Of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| BR112016020643B1 (pt) | 2014-03-06 | 2023-05-02 | National Research Council Of Canada | Anticorpos específicos para receptor de fator de crescimento semelhante à insulina tipo 1 e uso dos mesmos |
| KR101706296B1 (ko) | 2015-12-21 | 2017-02-13 | 주식회사 브레인온 | 기억력, 학습력, 인지력 향상용 조성물 |
| CA2965840C (en) | 2015-12-21 | 2021-11-30 | Brainon Inc. | A composition for improving memory, learning ability, and cognitive ability |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6329508B1 (en) | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| JPH06228199A (ja) * | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
| EP1006184A1 (en) * | 1998-12-03 | 2000-06-07 | F. Hoffmann-La Roche Ag | IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof |
| US20100293669A2 (en) * | 1999-05-06 | 2010-11-18 | Jingdong Liu | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| WO2001007084A1 (en) | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
| DE60032255T2 (de) | 1999-10-04 | 2007-06-28 | Nektar Therapeutics Al, Corp., Huntsville | Polymer-stabilisierte neuropeptide |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| AU2002214545B2 (en) | 2000-09-26 | 2008-04-03 | Genentech, Inc. | IGE receptor antagonists |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| AU2003220557A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US8017151B2 (en) | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
| BRPI0611800A2 (pt) * | 2005-06-15 | 2008-12-09 | Schering Corp | formulaÇço estÁvel de anticorpo |
| US8142781B2 (en) | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| WO2008143679A2 (en) * | 2006-06-01 | 2008-11-27 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
| AU2008296386A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
-
2011
- 2011-05-25 PL PL11787324T patent/PL2575846T3/pl unknown
- 2011-05-25 RS RS20150591A patent/RS54278B1/sr unknown
- 2011-05-25 CA CA2800744A patent/CA2800744C/en active Active
- 2011-05-25 SI SI201130557T patent/SI2575846T1/sl unknown
- 2011-05-25 US US13/115,523 patent/US8415306B2/en not_active Expired - Fee Related
- 2011-05-25 ME MEP-2015-146A patent/ME02206B/me unknown
- 2011-05-25 ES ES11787324.0T patent/ES2550040T3/es active Active
- 2011-05-25 CN CN201180025866.2A patent/CN103025341B/zh not_active Expired - Fee Related
- 2011-05-25 MX MX2012013710A patent/MX337134B/es active IP Right Grant
- 2011-05-25 EA EA201291416A patent/EA023541B1/ru unknown
- 2011-05-25 EP EP11787324.0A patent/EP2575846B1/en active Active
- 2011-05-25 HU HUE11787324A patent/HUE026269T2/en unknown
- 2011-05-25 DK DK11787324.0T patent/DK2575846T3/en active
- 2011-05-25 AU AU2011258301A patent/AU2011258301B2/en not_active Ceased
- 2011-05-25 UA UAA201214969A patent/UA107596C2/ru unknown
- 2011-05-25 HR HRP20151084TT patent/HRP20151084T1/hr unknown
- 2011-05-25 SG SG2012086617A patent/SG186068A1/en unknown
- 2011-05-25 PT PT117873240T patent/PT2575846E/pt unknown
- 2011-05-25 KR KR1020127033486A patent/KR101898502B1/ko not_active Expired - Fee Related
- 2011-05-25 NZ NZ603611A patent/NZ603611A/en not_active IP Right Cessation
- 2011-05-25 BR BR112012030084A patent/BR112012030084B1/pt not_active IP Right Cessation
- 2011-05-25 WO PCT/US2011/037904 patent/WO2011150061A1/en not_active Ceased
- 2011-05-25 JP JP2013512202A patent/JP5864556B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-14 IL IL223030A patent/IL223030A/en active IP Right Grant
- 2012-12-20 ZA ZA2012/09689A patent/ZA201209689B/en unknown
-
2015
- 2015-09-22 SM SM201500222T patent/SMT201500222B/xx unknown
- 2015-10-05 CY CY20151100883T patent/CY1116757T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| Chauhan et al. | The taming of the cell penetrating domain of the HIV Tat: myths and realities | |
| Flores-Pérez et al. | Molecular chaperone involvement in chloroplast protein import | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| ME02206B (me) | Receptor insulinu-sličnog faktora rasta 1 vezujući peptidi | |
| HRP20200988T1 (hr) | Nova imunoterapija protiv nekoliko tumora, uključujući tumore neurona i mozga | |
| HRP20161531T1 (hr) | Fc fuzijski proteini koji sadrže nove linkere ili aranžmane | |
| WO2011123813A3 (en) | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same | |
| EA201270802A1 (ru) | Димерные слитые белки vstm3 и связанные с ними композиции и способы | |
| HRP20190799T1 (hr) | Imunocitokini na bazi il-15 i sushi domene il-15r alfa | |
| HRP20220734T1 (hr) | Koagonisti glukagona i glp-1 za liječenje pretilosti | |
| JP2012531208A5 (me) | ||
| HRP20220649T1 (hr) | Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu | |
| WO2013024059A3 (en) | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies | |
| JP2013531477A5 (me) | ||
| HRP20130194T1 (hr) | Imunosupresivni polipeptidi i nukleinske kiseline | |
| MX2011009810A (es) | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. | |
| WO2012159006A3 (en) | Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof | |
| WO2011113027A3 (en) | Npp1 fusion proteins | |
| JP2014509851A5 (me) | ||
| HRP20181055T1 (hr) | Antagonisti kv1.3 i postupci upotrebe | |
| WO2014097113A3 (en) | Production of therapeutic proteins in genetically modified mammalian cells | |
| MX361434B (es) | Proteínas de fusión npp1. | |
| AU2015231210A1 (en) | Stabilized fibronectin based scaffold molecules | |
| JP2015524403A5 (me) |